<DOC>
	<DOCNO>NCT02957630</DOCNO>
	<brief_summary>The propose study provide assessment effect combination endocrine function , metabolic control hemostasis 6 treatment cycle . This compare effect two reference COCs .</brief_summary>
	<brief_title>`` E4/DRSP Endocrine Function , Metabolic Control Hemostasis Study ''</brief_title>
	<detailed_description />
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Healthy adult woman Negative pregnancy test subject screen randomization Aged 1850 year ( inclusive ) time sign ICF Good physical mental health basis medical , surgical gynecological history , physical examination , gynecological examination , clinical laboratory , ECG , echocardiography vital sign BMI 18.0 30.0 kg/m² , inclusive , time screen visit Able fulfil requirement protocol indicated willingness participate study provide write informed consent Known hypersensitivity investigational product ingredient Smoking &gt; 35 year old Dyslipoproteinemia use antilipidemic agent Known diabetes mellitus Current use antidiabetic drug , include insulin Arterial hypertension Any condition associate increase risk venous thromboembolism and/or arterial thromboembolism . Any condition associate abnormal uterine/vaginal bleeding . Presence undiagnosed breast mass Current symptomatic gallbladder disease History pregnancy COCrelated cholestasis Presence history severe hepatic disease Presence history pancreatitis associate hypertriglyceridemia Porphyria Presence history benign liver tumor ( focal nodular hyperplasia hepatocellular adenoma ) Presence renal impairment ( glomerular filtration rate [ GFR ] &lt; 60 mL/min/1.73m² ) Hyperkalemia presence condition predispose hyperkalemia Presence history hormonerelated malignancy History nonhormonerelated malignancy within 5 year screen ; subject nonmelanoma skin cancer allow study Use drug potentially trigger interaction COCs History alcohol drug abuse within 12 month prior screen Presence history thyroid disorder Participation another investigational drug clinical study within 1 month ( 30 day ) receive investigational drug within last 3 month ( 90 day ) prior randomization . Subjects participate oral contraceptive clinical study use Food Drug Administration ( FDA ) /European Union ( EU ) approve active ingredient , may randomize 2 month ( 60 day ) complete precede study Sponsor , contract research organization ( CRO ) Principal Investigator 's ( PI 's ) site personnel directly affiliate study Is judge PI unsuitable reason</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Estetrol ( E4 )</keyword>
	<keyword>Drospirenone ( DRSP )</keyword>
	<keyword>Ethinylestradiol ( EE )</keyword>
	<keyword>Levonorgestrel ( LNG )</keyword>
	<keyword>Oral contraceptive</keyword>
	<keyword>Prevention pregnancy</keyword>
	<keyword>Hemostasis</keyword>
	<keyword>Metabolism</keyword>
</DOC>